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INTRODUCTION
The number of patients with endometrial cancer is increasing 
in Japan as well as in the United States and other countries [1]. 
A majority of endometrial cancer patients are diagnosed as 
being without clinical evidence of extrauterine spread (FIGO 
stage I and II) and have a 5-year survival of approximately 
90%. Approximately 10% to 15% of patients with early 
stage endometrial cancer will experience recurrences [2,3]. 
To reduce the recurrence rate, adjuvant chemotherapy or 
radiotherapy has been applied. However, a definite standard 
therapy has not yet been established. 
Recently, the number of patients with recurrent endometrial 
cancer and advanced-stage disease is also increasing. For 
stage III-IV endometrial cancer, Randall et al. [4] recently 
reported that platinum-doxorubicin (AP) chemotherapy 
showed significantly better survival effect than whole 
abdominal irradiation (WAI) as an adjuvant treatment for 
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advanced-stage endometrial cancer. Although cytotoxic 
chemotherapy has been used primarily as palliative therapy for 
patients with advanced endometrial cancer, there is relatively 
little experience with postoperative systemic chemotherapy 
used as an adjuvant treatment in western countries. However, 
with the introduction of routine surgical staging, we have 
performed extensive surgery including systematic pelvic and 
para-aortic lymphadenectomy and post-surgical cisplatin-
based systemic chemotherapy for patients with intermediate 
or high risk of recurrence [5,6]. We have recently reported the 
prognosis and failure pattern of endometrial cancer patients 
treated with our treatment strategy, demonstrating better 
survival of node-positive patients with endometrial cancer 
compared to that reported in the literature [6]. We also 
revealed that distant failure was the most prevalent pattern of 
failure in spite of systemic adjuvant chemotherapy, suggesting 
that we need to optimize primary treatment and treatment 
after relapse to further improve survival of endometrial cancer [6].
While endometrial cancer is a highly curable malignancy 
when it presents as a uterine-confined disease, the prognosis 
for recurrent or metastatic disease is poor. The median 
survival of women enrolled in trials for recurrent or metastatic 
endometrial cancer hardly exceeds 12 months [7]. There 
is still no agreement in the literature regarding the most 
adequate treatment for those patients. Thus, it is important to 
establish a prognostic model to predict survival after relapse 
in endometrial cancer.
Therefore, the aim of this retrospective study was to 
determine the factors influencing survival of relapsing 
patients, and to assess an alternative strategy to routine 
adjuvant chemotherapy.
MATERIALS AND METHODS
1. Patients
A total of 316 patients with endometrial cancer underwent 
primary treatment with complete cytoreductive surgery 
and adjuvant chemotherapy from 1995 to 2008 at the 
Department of Obstetrics and Gynecology, Hokkaido 
University Hospital. All subjects underwent modified radical 
hysterectomy, bilateral salpingo-oophorectomy with 
systematic retroperitoneal lymphadenectomy [5,6]. Some 
patients did not receive lymphadenectomy because of their 
performance status or personal refusal. Thirty-five patients, 
whose complete follow-up information (especially exact date 
of relapse, treatment modality, and survival information) after 
relapse was available, were registered in this retrospective 
study. Stage IV disease with distant metastasis (liver or lung 
metastasis) was excluded from this analysis. We therefore 
defined stage IV patients showing peritoneal metastasis. In 
this study, we defined the patients with high risk or low risk for 
recurrence as those having stage III/IV disease or stage IA/IB 
with no/minimal lymphovascular space invasion, respectively. 
The others are classified as the intermediate risk group. All 
patients with intermediate or high risk for recurrence were 
usually treated with platinum-based adjuvant chemotherapy 
(cyclophosphamide, 350 mg/m
2; adriamycin, 40 mg/m
2 and 
cisplatin, 50-70 mg/m
2 or paclitaxel, 175 mg/m
2; carboplatin, 
AUC5) every 3 weeks when necessary. We administered six 
cycles of chemotherapy after the initial surgery.
Disease-relapse was diagnosed when physical examination 
with cytological or pathological examination, and systemic 
enhanced CT indicated recurrent or metastatic tumors during 
the follow-up period. Patterns of failure were divided into 
two groups, intrapelvic failures (vaginal or pelvic failure) and 
extrapelvic failures (distant failure and peritoneal failure) in 
this study. In cases with both failures, they were included in 
the extrapelvic failure group.
The following clinicopathological factors were included 
in this survival analysis: risk for recurrence described above, 
histologic type (endometrioid vs. non-endometrioid), time 
to relapse after primary surgery (within one year vs. over 
one year), number of relapse sites (single vs. multiple), site 
of relapse (intrapelvic vs. extrapelvic), treatment modality 
(chemotherapy alone vs. multimodalities), complete resection 
of recurrent tumors. Extrapelvic failures also included 
simultaneous failures to intrapelvic and extrapelvic sites in this 
analysis. Multiple relapse sites included metastasis to multiple 
organs, multiple metastatic lesions in the same organ, and 
peritoneal dissemination in this study.
   
2. Statistics
Patient survival was calculated using the Kaplan-Meier 
method. The significance of the survival difference was 
examined by the log-rank test. A p<0.05 was considered 
statistically significant. Statistical analyses were performed 
with the Statview (SAS Inc., Cary, NC, USA) as previously 
described [5,6].
RESULTS
1. Relapse site and treatment modality for recurrent 
endometrial cancer
Clinicopathological characteristics of thirty-five patients with 
recurrent endometrial cancer at initial treatment are listed in 
Table 1. The median age was fifty-seven years (range, 14 to 73 Multivariate survival analysis of recurrent endometrial cancer
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years). The median follow-up period after primary surgery was 
41 months (range, 2 to 161 months). According to the results 
of surgical staging, we provided adjuvant therapy for patients 
with risk for disease recurrence, including twelve intermediate 
risk and twenty high risk patients. Three patients with low risk 
for recurrence did not receive any adjuvant therapy. Median 
duration for progression from primary surgery was 20 months 
(range, 1 to 79 months). Median survival after relapse was 19 
months (range, 1 to 121 months). 
Among thirty-five patients, eight patients resulted in 
intrapelvic failure (four, vaginal; four, pelvic), twenty-seven 
extrapelvic failure (twenty, distant; four, peritoneal; and three, 
both). Seventeen patients received systemic platinum-based 
chemotherapy alone, eighteen multimodalities consisting 
of combination of debulking surgery, chemotherapy, or 
radiotherapy. We administered mainly taxane/platinum 
(paclitaxel or docetaxel and carboplatin) for recurrent disease 
(21 cases). Some patients received AP (adriamycin/cisplatin) 
regimen (five cases), and others (two cases). Five patients 
received debulking surgery with complete resection of 
recurrent tumors followed by adjuvant therapy. 
Table 1. Clinicopathological characteristics of recurrent endometrial 
cancer
Factor No. (%)
FIGO stage
  I/II 15 (42.9)
  III/IV 20 (57.1)
Histologic type
  Endometrioid 22 (62.9)
  Non-endometrioid 13 (37.1)
Grade
  G1 3 (8.6)
  G2 21 (60.0)
  G3 11 (31.4)
Myoinvasion
  ≤1/2 14 (40.0)
  >1/2 21 (60.0)
Lymphovascular space invasion*
  (-)/(+) 24 (68.6)
  (++)/(+++) 11 (31.4)
Cervical invasion
  (-) 28 (80.0)
  (+)   7 (20.0)
Ovarian metastasis
  (-) 24 (68.6)
  (+) 11 (31.4)
Lymph node metastasis
  (-) 22 (62.9)
  (+)    8 (22.8)
  Unknown   5 (14.3)
Risk of recurrence
  Low/intermediate 15 (42.9)
  High 20 (57.1)
*Lymphovascular space invasion was graded as previously described 
by Nishiya et al. [8].
Table 2. Risk factors related to survival after recurrence
Factor No. (%)
Histologic type
  Endometrioid 22 (62.9)
  Non-endometrioid 13 (37.1)
Risk for recurrence
  Low/intermediate 15 (42.9)
  High 20 (57.1)
Time to relapse
  Over one year 11 (31.4)
  Within one year 24 (68.6)
No. of relapse sites
  Single 13 (37.1)
  Multiple 22 (62.9)
Relapse site
  Intrapelvic   8 (22.9)
  Extrapelvic 27 (77.1)
Complete surgical resection
  (+)   5 (14.3)
  (-) 30 (85.7)
Treatment modality
  Multimodality 18 (51.4)
  Chemotherapy alone 17 (48.6)
Table 3. Multivariate analysis on risk factors for recurrent endometrial 
cancer
Univariate Multivariate
Clinicopathologic factor p-value Risk ratio 95% CI p-value
Histologic type 0.04   2.4 0.8-6.8 0.11
Risk for recurrence 0.07 - - -
Time to relapse 0.03   6.8 1.9-25.0 0.004
Number of relapse sites 0.03 11.1 2.3-52.6 0.002
Site of relapse 0.11 - - -
Complete surgical resection 0.22 - - -
Treatment modality 0.45 - - -
CI: confidence interval.Tetsuji Odagiri, et al.
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Univariate and multivariate survival analysis for the patients 
with recurrent disease (Tables 2 and 3, Fig. 1).
Table 2 shows the result of distribution of seven clinico-
pathological factors in thirty-five patients. Among the clinico-
pathological factors analyzed, histologic type (p=0.04), time to 
relapse after primary surgery (p=0.03), and number of relapse 
sites (p=0.03) were related to survival after relapse. Risk for 
recurrence showed marginal significance for survival (p=0.07), 
while site of relapse (p=0.11), treatment modality (p=0.45), 
and complete resection of recurrent tumors (p=0.22) did not 
show prognostic significance for recurrent endometrial cancer 
in our patient cohort. Multivariate analysis revealed that time 
to relapse after primary surgery (hazard ratio, 6.8; p=0.004) 
and number of relapse sites (hazard ratio, 11.1; p=0.002) 
were independent prognostic factors for survival after 
relapse. Histologic type was found not to be an independent 
prognosticator (p=0.11) (Table 3).
Survival after relapse of patients with recurrent disease could 
be stratified into three groups by the combination of two 
independent prognosticators. An estimated 3-year survival 
rate for the patients with single relapse site, irrespective of 
time to relapse (group A, n=12), was 64.9 %, and for multiple 
relapse sites with relapse over one year (group B, n=17) 
was 39.2 %. The patients with multiple relapse sites who 
relapsed within one year (group C, n=6) did not reach 3 years 
after relapse (33.3 % at 16 months). There was statistically 
significant difference of survival among each group (p=0.001 
for group A vs. group C, p=0.04 for group A vs. group B, 
p=0.02 for group B vs. group C) (Fig. 1).
DISCUSSION
In the present study, we analyzed the prognosticators for 
survival after relapse in patients with recurrent endometrial 
cancer who underwent primary complete cytoreductive 
surgery combined mainly with adjuvant chemotherapy. We 
first demonstrated that time to relapse after primary surgery 
and the number of relapse sites are independent prognostic 
factors for survival of recurrent endometrial cancer in this 
study. 
In the literature, prognostic analyses have been reported 
for patients with recurrent endometrial cancer who received 
primary surgery and adjuvant radiotherapy. Previously 
reported studies had indicated histological grading of the 
tumor [9,10] and time to progression interval [10] as the most 
important prognostic factors in the recurrent and metastatic 
cancer setting. Sartori et al. [11] previously reported that 
site of relapse, the interval of time from original surgery to 
recurrence, and whether postoperative pelvic radiotherapy 
was administered were independent prognostic variables 
for survival by multivariate analysis in recurrent endometrial 
cancer. Sohaib et al. [12] reported that multivariate analysis 
identified multiple sites of disease, liver and splenic metastases 
to be independent predictors of poor outcome in recurrent 
endometrial cancer. Thus, this study may be the first report, 
as far as we know, on the prognostic analysis for patients with 
recurrent endometrial cancer treated with primary surgery 
and adjuvant chemotherapy.
Although the exact reason why two factors are indepen-
dently related to survival after relapse remains to be deter-
mined, it is easy to speculate the possible reasons. Time to 
relapse within one year after primary surgery may largely 
depend on the aggressive phenotype and resistance to 
adjuvant chemotherapy of endometrial cancer cells, and 
multiple sites of recurrence may be related to the metastatic 
potential of endometrial cancer cells. Therefore, we need to 
establish a new treatment strategy to efficiently treat patients 
with recurrent endometrial cancer in addition to currently 
available treatment modalities including debulking surgery, 
chemotherapy, and radiotherapy. One of the promising 
molecular targeting agents is the vascular endothelial growth 
factor inhibitor, bevacizumab, which has been recently shown 
to improve progression-free survival of the patients with 
ovarian cancer [13]. To search for new molecular markers to 
predict survival after relapse and/or new molecular targets to 
improve survival, we need to further investigate the molecular 
mechanism of chemoresistance and radioresistance in 
endometrial cancer cells. Cyr61, a member of CCN family, may 
be a good target because Cyr61 predicts survival of patients 
Fig. 1. Stratificatiion of survival of patients with recurrent endometrial 
cancer by the combination of two independent prognostic factors. 
Survival after relapse with recurrent endometrial cancer was stratified 
into three groups according to the combination of time to relapse 
after primary surgery and number of relapse sites. Survival after 
relapse was significantly different between each group.Multivariate survival analysis of recurrent endometrial cancer
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with endometrial cancer [14], and has been reported to 
induce resistance to carboplatin in ovarian cancer cells [15] 
and resistance to paclitaxel in breast cancer [16]. Additionally, 
we need to investigate the molecular mechanism on the 
metastasis and invasion process of endometrial cancer cells. 
Complete resection of recurrent tumors has been reported 
to be a prognosticator for recurrent endometrial cancer in the 
literature [17], while this is not related to survival in our patient 
cohort. This may be due to the small number of analyzed 
cases. Another possibility is because debulking surgery is 
usually applied to selected patients with a single relapse 
site, which was independent prognostic factor for survival 
after relapse in this study. Histologic type was significantly 
related to survival after relapse in univariate analysis, whereas 
not after multivariate analysis in this study. This is probably 
because the patients with non-endometrioid histology tend 
to recur with shorter progression-free survival than those 
with endometrioid types, and time to relapse within one year 
after primary surgery was an independent prognostic factor 
in this study. Similar to all retrospective studies, the number 
of patients is fairly small and our findings need to be further 
validated in larger cohorts. 
Since the prognosis of the patients with recurrent 
endometrial cancer generally remains poor, and risk for 
recurrence showed marginal significance for survival after 
relapse in this study as well as in our previous study [17], we 
need to reconsider the current best treatment strategy as a 
primary treatment. We have recently shown that para-aortic 
lymphadenectomy significantly improves recurrence-free 
survival and overall survival of endometrial cancer patients 
with intermediate or high risk for recurrence [18]. Therefore, 
we should offer a better treatment strategy consisting 
of extensive surgery including systematic para-aortic 
lymphadenectomy and systemic adjuvant chemotherapy to 
provide better survival benefit for patients with intermediate/
high risk for recurrence. On the contrary, endometrial cancer 
patients with low risk for recurrence may not need to receive 
neither adjuvant treatment nor extensive lymphadenectomy 
including para-aortic nodes as previously reported by Mariani, 
et al. [19]. 
In summary, time to relapse after primary surgery and the 
number of relapse sites are independent prognosticators for 
survival after relapse in patients with recurrent endometrial 
cancer. We need to offer the opportunity to participate in 
clinical trials to establish new treatment strategies using 
molecular targeting drugs for recurrent endometrial cancer 
patients. We also need to further investigate the molecular 
mechanisms governing sensitivity to chemotherapy and 
radiotherapy, and the metastatic processes in endometrial 
cancer cells to establish new treatment strategy for recurrent 
cases.
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